Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans.

Background: Topiramate, which is increasingly being used to treat alcohol use disorder (AUD), is commonly associated with reduced serum bicarbonate concentrations. However, estimates of the prevalence and magnitude of this effect are from small samples and do not address whether topiramate's effects on acid–base balance differ in the presence of an AUD or by topiramate dosage. Methods: Veterans Health Administration electronic health record (EHR) data were used to identify patients with a minimum of 180 days of topiramate prescription for any indication and a propensity score‐matched control group. We differentiated patients into two subgroups based on the presence of a diagnosis of AUD in the EHR. Baseline alcohol consumption was determined using Alcohol Use Disorders Identification Test–Consumption (AUDIT‐C) scores in the EHR. Analysis also included a three‐level measure representing mean daily dosage. The topiramate‐associated changes in serum bicarbonate concentration were estimated in difference‐in‐differences linear regression models. A serum bicarbonate concentration <17 mEq/L was considered to represent possible clinically significant metabolic acidosis. Results: The cohort comprised 4287 topiramate‐treated patients and 5992 propensity score‐matched controls with a mean follow‐up period of 417 days. The mean topiramate‐associated reductions in serum bicarbonate concentration were <2 mEq/L in the low (≤88.75), medium (>88.75 and ≤141.70), and high (>141.70) mg/day dosage tertiles, irrespective of AUD history. Concentrations <17 mEq/L occurred in 1.1% of topiramate‐treated patients and 0.3% of controls and were not associated with alcohol consumption or an AUD diagnosis. Conclusions: The excess prevalence of metabolic acidosis associated with topiramate treatment does not differ with dosage, alcohol consumption, or the presence of an AUD. Baseline and periodic serum bicarbonate concentration measurements are recommended during topiramate therapy. Patients prescribed topiramate should be educated about the symptoms of metabolic acidosis and urged to report their occurrence promptly to a healthcare provider. [ABSTRACT FROM AUTHOR]